Organon
Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
DitchCarbon Score
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon's score of 24 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organon's reported carbon emissions
In 2023, Organon reported carbon emissions of approximately 2,272,000 kg CO2e for Scope 1, 5,557,000 kg CO2e for Scope 2, and 2,500,000 kg CO2e for Scope 3 in the UK. This reflects a commitment to transparency in their emissions reporting, although specific reduction targets or initiatives have not been disclosed. In 2022, their global emissions included about 30,360,000 kg CO2e for Scope 1, 30,907,000 kg CO2e for Scope 2, and a significant 1,029,000,000 kg CO2e for Scope 3, indicating a substantial impact from their supply chain and product use. The UK emissions for 2022 were approximately 1,122,000 kg CO2e for Scope 1, 5,677,000 kg CO2e for Scope 2, and 5,370,000 kg CO2e for Scope 3. Organon has not set specific reduction targets under the Science Based Targets initiative (SBTi) or other formal climate pledges, which places them in a broader industry context where many companies are increasingly committing to measurable climate action. Their emissions data highlights the importance of addressing both direct and indirect emissions to achieve meaningful climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organon is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
